ClinicalTrials.gg

Program

HIF-2alpha Inhibitor HS-10516

Also written as “HS-10516 + Lenvatinib”, “Oral HS-10516” and “HS-10516”.

Its studies are mostly in Carcinoma, Renal Cell · von Hippel-Lindau Disease, led by Hansoh Pharmaceutical Group.

Furthest: phase 2, since Jul 30, 20253 company-led studies, 3 open or runningNext primary completion: Jul 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group33 open or runningphase 2since Jul 30, 2025Sep 15, 2023Jul 10, 2027phase 2 · NCT07097935

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2023First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT06049030 · 190 planned
  2. Aug 12, 2024Phase 1 study in von Hippel-Lindau DiseaseNCT06553339 · 60 planned · China
  3. Jul 30, 2025Phase 2 study in Advanced Clear Cell Renal Cell CarcinomaNCT07097935 · 104 planned · China

Ahead

  1. Jul 10, 2027Primary completion: phase 2 study in Advanced Clear Cell Renal Cell CarcinomaNCT07097935

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07097935Advanced Clear Cell Renal Cell Carcinoma · China2RecruitingJul 10, 2027104
NCT06553339von Hippel-Lindau Disease · China1RecruitingJul 31, 202660
NCT06049030Carcinoma, Renal Cell1Not yet recruitingSep 25, 2024190

How it is read

Names in the registry

  • “HS-10516 + Lenvatinib”, 1 entry
  • “Oral HS-10516”, 1 entry
  • “HS-10516”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.